NUTRIGENOMICS
Understand how your body responds to foods and nutrients
Explore
- Technology
- Our Products
- About Us
Explore
Prenetics is the leading genetic testing/digital health company in Southeast Asia.
We empower individuals with valuable health information. With a simple saliva sample, individuals can discover how their genes affect their diet, drug response, disease and cancer risk.
This information enables people to make health a choice, by living healthier and proactively preventing diseases.
Danny Yeung
Chief Executive Officer - Prenetics Group
Danny Yeung is the Chief Executive Officer of Prenetics Group and sets business strategies and vision. Prior to Prenetics, Danny led multiple investments in DNA Genetic testing companies as Founding Partner/Investor at SXE Ventures. Previously, Danny founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to Danny leaving Groupon in early 2014, Danny served as CEO of Groupon East Asia, having scaled the business to a size of over USD $130m annually, overseeing a staff of 350 and being highly profitable. Danny’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong's award-winning dessert chain Hui Lau Shan into USA. After exiting Hui Lau Shan, Danny successfully ventured into hospitality furniture and executed multi-million dollar projects with MGM City Center, City of Dreams Macau and Venetian. Danny is currently a Founding Partner at SXE Ventures, Board Member at Parabase Genomics, Limited Partner and Mentor for 500 Startups. Danny received his BS in MIS from the University of San Francisco. Danny’s life motto is “Play Hard, Work Harder”.
Avi Lasarow
Chief Executive Officer (Europe, Middle East and Africa)
Avi Lasarow is the Chief Executive Officer (Europe, Middle East and Africa) of Prenetics, responsible for international market growth outside of Asia Pacific and Americas. An award-winning lifestyle genetics pioneer on a mission to help people live happier and healthier lives, Avi has dedicated over a quarter of his life in the relentless pursuit of science and technological innovation. Avi’s career began at the consumer financial giant Citibank, before making a transition into founding a number of successful life sciences companies. The youngest ever Honorary Consul for South Africa to UK, Avi’s companies have also been highly decorated. In 2018 DNAFit received two Queens Awards for Enterprise, as well as a Board of Trade Award from the Department for International Trade. With Prenetics, he remains driven to advance and humanise a science that once seemed unreachable and inaccessible to so many.
Dr. Lawrence Tzang, Ph.D.
Co-Founder and Chief Scientific Officer
Dr. Tzang is the Co-Founder and Chief Scientific Officer of Prenetics. Dr. Tzang is recognized as a leader in DNA based Molecular Diagnostic Techniques. Dr. Tzang has over 15 years industry experience and has spear-headed the development of over 30 proprietary panels, including DNA Microarray and Microfluidic platforms which has been used in research and in clinical settings. Dr. Tzang is also a Founding Member of the Hong Kong Society for Behavioural and Neural Genetics. Dr. Tzang holds seven global patents/patent applications and has authored 30 scientific articles. Dr. Tzang received his Ph.D in Genetics from City University of Hong Kong.
Stephen Lo
Chief Financial Officer
Stephen is the Chief Financial Officer of Prenetics, and oversees the accounting, finance, and operations functions. Before joining Prenetics, Stephen was a Vice President in the Asia Pacific Investment Banking team of Citigroup, where he completed initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the US. Prior to investment banking, Stephen was a senior auditor with Ernst & Young. Stephen graduated from Yale University’s School of Management, the London School of Economics and Political Science and Hong Kong Baptist University. He is a Certified Public Accountant and has completed the CFA Program.
Dr. Peter Wong, DPhil
Chief Technology Officer
Dr. Wong, DPhil (Oxon), is the Chief Technology Officer of Prenetics and is responsible for driving technology vision and roadmap, and engineering delivery. Prior to Prenetics, Peter was the Head of Engineering at Travelex, where he led its first digital transformation and successfully delivered a brand new international money transfer service, Travelex Wire. Peter also led Travelex's B2B business, and launched its first international payment platform with the World Bank Group. Peter has experience across various industries including investment banking and eCommerce; and is a frequent speaker at technology events such as AWS Summit and at universities. Peter holds a Doctorate degree in Computer Science from the University of Oxford, and BSc and MSc degrees in Computer Science from the University of Warwick.
Dr. Senthil Sundaram, MD
Chief Clinical Officer
Dr. Sundaram, MD, is the Chief Clinical Officer of Prenetics. Dr. Sundaram is highly recognised for his experience as a physician-scientist，having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases using cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram’s research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram’s research works have been funded by the National Institute of Health (NIH), USA. Dr. Sundaram also serves as a reviewer of different journals and NIH study sections.
Dr. Belinda Cheung, Ph.D.
Vice President (Research & Development)
Dr. Cheung serves as Vice President (Research & Development) and has been instrumental in the creation of the company’s proprietary assay platform. Dr. Cheung has over 13 years In-Vitro Diagnostic (IVD) industry experience in product development as well as clinical settings. Dr. Cheung managed over 18 M HKD grants, and was previously the Principal Researcher in a joint collaboration study between Hong Kong Government and a consortium of listed companies in the bio-tech space. Dr. Cheung holds 7 global patents /patent applications and has published 16 scientific articles. Dr. Cheung received her Ph.D in Biochemistry from The Hong Kong Polytechnic University.
Prof. Michael M Yang, PhD
Head of Department of Biomedical Sciences; Chair Professor of Chemistry and Biomedical Sciences, City University of Hong Kong
Professor Yang is a co-founder of Prenetics (formerly named Multigene) as a spin-off from City University focusing on the development of molecular diagnostics for early detection of diseases. Professor Yang’s research interest focuses on the development of biochip technology and nanomedicine for basic research and clinical applications. Professor Yang has published over 200 peer-reviewed scientific papers and obtained 23 patents. He has delivered more than 160 invited lectures in international conferences and universities, and trained 24 PhD/M.Phil. students and numerous postdoctoral fellows in his laboratory. He holds honorary professorships in Zhejiang University and the Third Military Medical University. Professor Yang serves in the grant review boards of Hong Kong Government Health and Medical Research Fund and Innovation and Technology Fund. He has been awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, and the Hong Kong Technological Achievement Grand Award in 2007. Professor Yang obtained his PhD from University of Toronto and postdoctoral training in the Scripps Research Institute in USA.
Prof. Stephen Tsui, PhD
Head of Division of Genomics and Bioinformatics, The Chinese University of Hong Kong
Prof. Tsui Kwok Wing Stephen is currently a Professor in the School of Biomedical Sciences, the Head of Division of Genomics and Bioinformatics and the Director of Hong Kong Bioinformatics Centre of the Chinese University of Hong Kong (CUHK). In 1995, he received his PhD degree in Biochemistry at CUHK. He was then appointed as an Assistant Professor in the Biochemistry Department in 1997 and promoted to the full professorship in 2004. He was also a former member of the International HapMap Consortium and worked on the single nucleotide polymorphisms of human chromosome 3p. During the SARS outbreak in 2003, his team was one of the earliest teams that cracked the complete genome of the SARS-coronavirus. Totally, he has published more than 176scientific papers in international journals, including Nature, NEJM, Lancet, PNAS, Circulation, JACI and Genome Biology and two US patents. His major research interests are next generation sequencing, bioinformatics, human genetic diseases and molecular microbiology.
Sandor Weyers
Prudential Corporation Asia - Former Chief Capital Officer
Sandor has held various senior leadership positions in the insurance industry in a career that spans over twenty years. He has worked for large multinational organisations in South Africa, the United States, Mexico, Taiwan and currently Hong Kong. Sandor was most recently the Chief Capital Officer for Prudential Corporation Asia’s regional business. He joined Prudential in 2009 and established the regional Capital Management function, growing Asia cashflow to the Global Headquarters from £40m in 2009 to £400m in 2013. Sandor established PCA Re in 2012, Prudential’s reinsurance captive, and was Chief Executive since inception. Prior to joining Prudential he was Vice President, Corporate Strategy, for AIG’s Greater China operations. Sandor is a leading expert in the insurance industry with an extensive global network.
Samita Malik
MetLife Asia - Former VP Health
Samita is a seasoned insurance executive with experience across North America, Europe and Asia. Most recently, she was responsible for the strategic growth of MetLife’s health business across Asia, a US$ 4bn portfolio with sales in excess of US$ 700M across 8 Asian markets. Previously, she held management positions with MetLife in both Hong Kong and New York. Prior to joining MetLife, Samita was a management consultant at Bain & Company and served several large multinational insurance clients. She started her insurance career at Anthem, Inc which is currently the largest health insurer in the US. Samita holds an MBA from The Wharton School at the University of Pennsylvania and an MA in Economics from the University of Virginia. She is extremely passionate about reshaping the health insurance industry around the needs of the customer and believes in the disruptive power of technology to help achieve that.
Andy A. Liu
IMS Health Asia and China - Former President
Andy A. Liu is currently the Vice Chairman of HKBIO. Mr. Liu has previously served as President of Asia Pacific and China for IMS Health, a TPG private equity portfolio company focusing on big data healthcare that went IPO in 2014. Mr. Liu was responsible for managing the P&L and entire business in the region inclusive of 16 countries/region in Asia: China, Australia, India, South Korea, New Zealand, Hong Kong, Taiwan, Vietnam, Indonesia, Philippines, Thailand, Singapore, Malaysia, Bangladesh, Sri Lanka and Pakistan. Previously he has served as Head of Strategy & Business Development for IMS Health where he was responsible for leading all M&A, investments, acquisitions, joint ventures, due diligence, deal transactions and partnerships in the Asia Pacific region.
Rolf Steffen
Zuellig Pharma - Former Chief Executive Officer, Healthcare
Mr Steffen has over twenty years of experience in senior leadership positions in the healthcare industry in Asia Pacific. He was most recently Chief Executive for Healthcare Services and Investments at Zuellig Pharma, a privately held healthcare services company with sales in excess of US$ 9bn and 11’000 employees. Mr Steffen joined Zuellig Pharma in 1993 and held management positions in Taiwan and the Philippines before his move to the Corporate Headquarters in Hong Kong in 2002 as Regional Director, responsible for the activities of the Group in the ASEAN countries, Taiwan and Hong Kong. As a leading expert in healthcare services, Mr Steffen has an extensive global industry network. He served on the Board of Overseers of the International Partnership for Innovative Healthcare Delivery, an organization catalysed by the World Economic Forum supporting innovators globally and connecting them to potential strategic partners and funders.
Shuhei Morofuji
Has a private jet but chooses to fly economy
Mr Morofuji is currently the Founder and CEO of REAPRA Pte Ltd. He was previously the Founder and CEO of SMS Co Ltd for 11 years which is one of the largest healthcare information platforms in Asia. SMS is listed on the Tokyo Stock Exchange with a market capitalization of over $700m USD.
Danny Yeung
Chief Executive Officer - Prenetics Group
Danny Yeung is the Chief Executive Officer of Prenetics Group and sets business strategies and vision. Prior to Prenetics, Danny led multiple investments in DNA Genetic testing companies as Founding Partner/Investor at SXE Ventures. Previously, Danny founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to Danny leaving Groupon in early 2014, Danny served as CEO of Groupon East Asia, having scaled the business to a size of over USD $130m annually, overseeing a staff of 350 and being highly profitable. Danny’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong's award-winning dessert chain Hui Lau Shan into USA. After exiting Hui Lau Shan, Danny successfully ventured into hospitality furniture and executed multi-million dollar projects with MGM City Center, City of Dreams Macau and Venetian. Danny is currently a Founding Partner at SXE Ventures, Board Member at Parabase Genomics, Limited Partner and Mentor for 500 Startups. Danny received his BS in MIS from the University of San Francisco. Danny’s life motto is “Play Hard, Work Harder”.
Avi Lasarow
Chief Executive Officer (Europe, Middle East and Africa)
Avi Lasarow is the Chief Executive Officer (Europe, Middle East and Africa) of Prenetics, responsible for international market growth outside of Asia Pacific and Americas. An award-winning lifestyle genetics pioneer on a mission to help people live happier and healthier lives, Avi has dedicated over a quarter of his life in the relentless pursuit of science and technological innovation. Avi’s career began at the consumer financial giant Citibank, before making a transition into founding a number of successful life sciences companies. The youngest ever Honorary Consul for South Africa to UK, Avi’s companies have also been highly decorated. In 2018 DNAFit received two Queens Awards for Enterprise, as well as a Board of Trade Award from the Department for International Trade. With Prenetics, he remains driven to advance and humanise a science that once seemed unreachable and inaccessible to so many.
Dr. Lawrence Tzang, Ph.D.
Co-Founder and Chief Scientific Officer
Dr. Tzang is the Co-Founder and Chief Scientific Officer of Prenetics. Dr. Tzang is recognized as a leader in DNA based Molecular Diagnostic Techniques. Dr. Tzang has over 15 years industry experience and has spear-headed the development of over 30 proprietary panels, including DNA Microarray and Microfluidic platforms which has been used in research and in clinical settings. Dr. Tzang is also a Founding Member of the Hong Kong Society for Behavioural and Neural Genetics. Dr. Tzang holds seven global patents/patent applications and has authored 30 scientific articles. Dr. Tzang received his Ph.D in Genetics from City University of Hong Kong.
Stephen Lo
Chief Financial Officer
Stephen is the Chief Financial Officer of Prenetics, and oversees the accounting, finance, and operations functions. Before joining Prenetics, Stephen was a Vice President in the Asia Pacific Investment Banking team of Citigroup, where he completed initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the US. Prior to investment banking, Stephen was a senior auditor with Ernst & Young. Stephen graduated from Yale University’s School of Management, the London School of Economics and Political Science and Hong Kong Baptist University. He is a Certified Public Accountant and has completed the CFA Program.
Dr. Peter Wong, DPhil
Chief Technology Officer
Dr. Wong, DPhil (Oxon), is the Chief Technology Officer of Prenetics and is responsible for driving technology vision and roadmap, and engineering delivery. Prior to Prenetics, Peter was the Head of Engineering at Travelex, where he led its first digital transformation and successfully delivered a brand new international money transfer service, Travelex Wire. Peter also led Travelex's B2B business, and launched its first international payment platform with the World Bank Group. Peter has experience across various industries including investment banking and eCommerce; and is a frequent speaker at technology events such as AWS Summit and at universities. Peter holds a Doctorate degree in Computer Science from the University of Oxford, and BSc and MSc degrees in Computer Science from the University of Warwick.
Dr. Senthil Sundaram, MD
Chief Clinical Officer
Dr. Sundaram, MD, is the Chief Clinical Officer of Prenetics. Dr. Sundaram is highly recognised for his experience as a physician-scientist，having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases using cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram’s research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram’s research works have been funded by the National Institute of Health (NIH), USA. Dr. Sundaram also serves as a reviewer of different journals and NIH study sections.
Dr. Belinda Cheung, Ph.D.
Vice President (Research & Development)
Dr. Cheung serves as Vice President (Research & Development) and has been instrumental in the creation of the company’s proprietary assay platform. Dr. Cheung has over 13 years In-Vitro Diagnostic (IVD) industry experience in product development as well as clinical settings. Dr. Cheung managed over 18 M HKD grants, and was previously the Principal Researcher in a joint collaboration study between Hong Kong Government and a consortium of listed companies in the bio-tech space. Dr. Cheung holds 7 global patents /patent applications and has published 16 scientific articles. Dr. Cheung received her Ph.D in Biochemistry from The Hong Kong Polytechnic University.
Prof. Michael M Yang, PhD
Head of Department of Biomedical Sciences; Chair Professor of Chemistry and Biomedical Sciences, City University of Hong Kong
Professor Yang is a co-founder of Prenetics (formerly named Multigene) as a spin-off from City University focusing on the development of molecular diagnostics for early detection of diseases. Professor Yang’s research interest focuses on the development of biochip technology and nanomedicine for basic research and clinical applications. Professor Yang has published over 200 peer-reviewed scientific papers and obtained 23 patents. He has delivered more than 160 invited lectures in international conferences and universities, and trained 24 PhD/M.Phil. students and numerous postdoctoral fellows in his laboratory. He holds honorary professorships in Zhejiang University and the Third Military Medical University. Professor Yang serves in the grant review boards of Hong Kong Government Health and Medical Research Fund and Innovation and Technology Fund. He has been awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, and the Hong Kong Technological Achievement Grand Award in 2007. Professor Yang obtained his PhD from University of Toronto and postdoctoral training in the Scripps Research Institute in USA.
Prof. Stephen Tsui, PhD
Head of Division of Genomics and Bioinformatics, The Chinese University of Hong Kong
Prof. Tsui Kwok Wing Stephen is currently a Professor in the School of Biomedical Sciences, the Head of Division of Genomics and Bioinformatics and the Director of Hong Kong Bioinformatics Centre of the Chinese University of Hong Kong (CUHK). In 1995, he received his PhD degree in Biochemistry at CUHK. He was then appointed as an Assistant Professor in the Biochemistry Department in 1997 and promoted to the full professorship in 2004. He was also a former member of the International HapMap Consortium and worked on the single nucleotide polymorphisms of human chromosome 3p. During the SARS outbreak in 2003, his team was one of the earliest teams that cracked the complete genome of the SARS-coronavirus. Totally, he has published more than 176scientific papers in international journals, including Nature, NEJM, Lancet, PNAS, Circulation, JACI and Genome Biology and two US patents. His major research interests are next generation sequencing, bioinformatics, human genetic diseases and molecular microbiology.
Sandor Weyers
Prudential Corporation Asia - Former Chief Capital Officer
Sandor has held various senior leadership positions in the insurance industry in a career that spans over twenty years. He has worked for large multinational organisations in South Africa, the United States, Mexico, Taiwan and currently Hong Kong. Sandor was most recently the Chief Capital Officer for Prudential Corporation Asia’s regional business. He joined Prudential in 2009 and established the regional Capital Management function, growing Asia cashflow to the Global Headquarters from £40m in 2009 to £400m in 2013. Sandor established PCA Re in 2012, Prudential’s reinsurance captive, and was Chief Executive since inception. Prior to joining Prudential he was Vice President, Corporate Strategy, for AIG’s Greater China operations. Sandor is a leading expert in the insurance industry with an extensive global network.
Samita Malik
MetLife Asia - Former VP Health
Samita is a seasoned insurance executive with experience across North America, Europe and Asia. Most recently, she was responsible for the strategic growth of MetLife’s health business across Asia, a US$ 4bn portfolio with sales in excess of US$ 700M across 8 Asian markets. Previously, she held management positions with MetLife in both Hong Kong and New York. Prior to joining MetLife, Samita was a management consultant at Bain & Company and served several large multinational insurance clients. She started her insurance career at Anthem, Inc which is currently the largest health insurer in the US. Samita holds an MBA from The Wharton School at the University of Pennsylvania and an MA in Economics from the University of Virginia. She is extremely passionate about reshaping the health insurance industry around the needs of the customer and believes in the disruptive power of technology to help achieve that.
Andy A. Liu
IMS Health Asia and China - Former President
Andy A. Liu is currently the Vice Chairman of HKBIO. Mr. Liu has previously served as President of Asia Pacific and China for IMS Health, a TPG private equity portfolio company focusing on big data healthcare that went IPO in 2014. Mr. Liu was responsible for managing the P&L and entire business in the region inclusive of 16 countries/region in Asia: China, Australia, India, South Korea, New Zealand, Hong Kong, Taiwan, Vietnam, Indonesia, Philippines, Thailand, Singapore, Malaysia, Bangladesh, Sri Lanka and Pakistan. Previously he has served as Head of Strategy & Business Development for IMS Health where he was responsible for leading all M&A, investments, acquisitions, joint ventures, due diligence, deal transactions and partnerships in the Asia Pacific region.
Rolf Steffen
Zuellig Pharma - Former Chief Executive Officer, Healthcare
Mr Steffen has over twenty years of experience in senior leadership positions in the healthcare industry in Asia Pacific. He was most recently Chief Executive for Healthcare Services and Investments at Zuellig Pharma, a privately held healthcare services company with sales in excess of US$ 9bn and 11’000 employees. Mr Steffen joined Zuellig Pharma in 1993 and held management positions in Taiwan and the Philippines before his move to the Corporate Headquarters in Hong Kong in 2002 as Regional Director, responsible for the activities of the Group in the ASEAN countries, Taiwan and Hong Kong. As a leading expert in healthcare services, Mr Steffen has an extensive global industry network. He served on the Board of Overseers of the International Partnership for Innovative Healthcare Delivery, an organization catalysed by the World Economic Forum supporting innovators globally and connecting them to potential strategic partners and funders.
Shuhei Morofuji
Has a private jet but chooses to fly economy
Mr Morofuji is currently the Founder and CEO of REAPRA Pte Ltd. He was previously the Founder and CEO of SMS Co Ltd for 11 years which is one of the largest healthcare information platforms in Asia. SMS is listed on the Tokyo Stock Exchange with a market capitalization of over $700m USD.
